US equities |
MU $1,045.56 ▲+0.00% AMD $649.42 ▲+0.00% NVDA $239.24 ▲+0.00% INTC $112.50 ▲+0.00% SNDK $1,660.46 ▲+0.00% SPCX $171.92 ▲+0.00% MRVL $287.01 ▲+0.00% PG $148.41 ▲+0.00%
FinancialContent

Applied DNA Sciences, Inc. - Common Stock (NQ:APDN)

5.620 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Applied DNA Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start
Via ACCESSWIRE
News headline image
Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress
Via ACCESSWIRE
News headline image
Recap: Applied DNA Sciences Q1 Earnings ↗
 
Via Benzinga
News headline image
Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results
Via ACCESSWIRE
News headline image
Earnings Scheduled For February 8, 2024 ↗
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million. 
Via Benzinga
News headline image
Earnings Preview For Applied DNA Sciences ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Applied DNA Sciences: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results
Via ACCESSWIRE
News headline image
Applied DNA Extends Application of Linea(TM) IVT Platform to saRNA (self-amplifying mRNA)
Via ACCESSWIRE
News headline image
Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024
Via ACCESSWIRE
News headline image
Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea(TM) DNA Platform
Via ACCESSWIRE
News headline image
Applied DNA Reports Third Quarter Fiscal 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
News headline image
Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow
Via ACCESSWIRE
News headline image
Lululemon To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
APDN Stock Earnings: Applied DNA Sciences Beats EPS, Misses Revenue for Q4 2023 ↗
APDN stock results show that Applied DNA Sciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Earnings Scheduled For December 7, 2023 ↗
Companies Reporting Before The Bell • IES Hldgs (NASDAQ:IESC) is expected to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Earnings Preview: Applied DNA Sciences ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023
Via ACCESSWIRE
News headline image
Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application
Via ACCESSWIRE
News headline image
Applied DNA Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals
Via ACCESSWIRE
News headline image
Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs
Via ACCESSWIRE
News headline image
Applied DNA Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit
Via ACCESSWIRE
News headline image
Applied DNA Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production
Via ACCESSWIRE
News headline image
Applied DNA to Report Third Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, August 10, 2023
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >